Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment
| Autor: | V. Robles, Pilar Nos, Claudia Herrera-de Guise, Alicia Algaba, Yolanda Ber Nieto, Guillermo Bastida, Esteban Sáez-González, Fernando Gomollón, Jose Manuel Soares, Fernando Bermejo |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Bastida G] Department of Gastroenterology, CIBEREHD, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain. [Herrera-de Guise C, Robles V] Unitat d'Atenció a la Colitis de Crohn, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Algaba A] Department of Gastroenterology, Instituto de Investigación Sanitaria Hospital La Paz (IdiPaz), Hospital Universitario de Fuenlabrada, 28046 Madrid, Spain. [Ber Nieto Y] Department of Gastroenterology, Hospital Universitario San Jorge, 22004 Huesca, Spain. [Soares JM] Department of Gastroenterology, Hospital Pedro Hispano, 4454-509 Matosinhos, Portugal, Vall d'Hebron Barcelona Hospital Campus, Servicio de Digestivo. Hospital Universitario de Fuenlabrada |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo del hierro::anemia ferropénica [ENFERMEDADES]
Male Inorganic Chemicals::Elements::Metals Heavy::Iron [CHEMICALS AND DRUGS] Administration Oral Gastroenterology Inflammatory bowel disease Ferric Compounds Intestins - Inflamació - Tractament enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal [ENFERMEDADES] Hemoglobins Enfermedades Inflamatorias del Intestino 0302 clinical medicine iron deficiency Quality of life Surveys and Questionnaires Compuestos de Hierro Anèmia ferropènica - Tractament TX341-641 Prospective Studies Prospective cohort study Depression (differential diagnoses) Aged 80 and over Nutrition and Dietetics Anemia Iron-Deficiency sucrosomial iron Iron deficiency Middle Aged anemia humanities compuestos inorgánicos::elementos::metales pesados::hierro [COMPUESTOS QUÍMICOS Y DROGAS] Anemia Ferropénica Treatment Outcome Tolerability 030220 oncology & carcinogenesis Other subheadings::Other subheadings::/administration & dosage [Other subheadings] 030211 gastroenterology & hepatology Female Adult medicine.medical_specialty Anemia Iron Article 03 medical and health sciences Young Adult inflammatory bowel disease Internal medicine medicine Humans Ferro - Metabolisme - Ús terapèutic Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases [DISEASES] Aged Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores] Nutrition. Foods and food supply business.industry iron supplementation Nutritional and Metabolic Diseases::Metabolic Diseases::Iron Metabolism Disorders::Anemia Iron-Deficiency [DISEASES] medicine.disease Inflammatory Bowel Diseases Trace Elements Iron-deficiency anemia Dietary Supplements Quality of Life business Iron Compounds Food Science |
| Zdroj: | Nutrients Volume 13 Issue 6 Scientia Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid Nutrients, Vol 13, Iss 1770, p 1770 (2021) |
| ISSN: | 2072-6643 |
| DOI: | 10.3390/nu13061770 |
| Popis: | Iron deficiency anemia (IDA) is a common manifestation of Inflammatory Bowel Disease (IBD). Oral iron supplements are the treatment of choice, but are not always well tolerated. Sucrosomial® iron (SI) may represent an alternative. This prospective study assessed the tolerability and effectiveness of SI, and quality of life (QoL) of IDA-IBD patients who were intolerant to oral iron salts. The study included 52 individuals treated with 1 capsule/day for 12 weeks. Tolerability was assessed through a gastrointestinal symptom severity questionnaire. Hemoglobin (Hb) levels and clinical symptoms of IDA were analyzed. QoL was assessed using IBDQ-9 and EuroQoL questionnaires. The percentage of patients with excellent/good health increased from 42.9% to 94.3%. Mean Hb concentration significantly increased at all follow-up visits (p < 0.05). Almost all participants (96.9%) were adherent to the study medication. Patients’ QoL improved (IBDQ-9: from 60.9 to 65.5). Patients also improved in mobility (71.8% to 78.1%), usual activities (51.3% to 68.7%), pain/discomfort (41.0% to 53.1%), and extreme depression/anxiety problems (7.7% to 3.2%) they worsened in self-care (100% to 90.6%), but perceived an enhancement in their global health [EQ-VAS score: 61.9 (±26.1) to 66.9 (±20.3)]. SI was well tolerated and improved IDA symptoms, IBD activity, and patients’ QoL. In conclusion, SI should be considered in IDA–IBD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|